Lung cancer biomarkers: Raising the clinical value of the classical and the new ones.

Q3 Biochemistry, Genetics and Molecular Biology

Tumor Biology Pub Date : 2024-01-01 DOI:10.3233/TUB-240004

Stefan Holdenrieder, Huub H van Rossum, Michel van den Heuvel

{"title":"Lung cancer biomarkers: Raising the clinical value of the classical and the new ones.","authors":"Stefan Holdenrieder, Huub H van Rossum, Michel van den Heuvel","doi":"10.3233/TUB-240004","DOIUrl":null,"url":null,"abstract":"<p><p>Blood-based diagnostics for lung cancer support the diagnosis, estimation of prognosis, prediction, and monitoring of therapy response in lung cancer patients. The clinical utility of serum tumor markers has considerably increased due to developments in serum protein tumor markers analytics and clinical biomarker studies, the exploration of preanalytical and influencing conditions, the interpretation of biomarker combinations and individual biomarker kinetics, as well as the implementation of biostatistical models. In addition, circulating tumor DNA (ctDNA) and other liquid biopsy markers are playing an increasingly prominent role in the molecular tumor characterization and the monitoring of tumor evolution over time. Thus, modern lung cancer biomarkers may considerably contribute to an individualized companion diagnostics and provide a sensitive guidance for patients throughout the course of their disease. In this special edition on Tumor Markers in Lung Cancer, experts summarize recent developments in clinical laboratory diagnostics of lung cancer and give an outlook on future challenges and opportunities.</p>","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":"46 s1","pages":"S1-S7"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumor Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/TUB-240004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 0

Abstract

Blood-based diagnostics for lung cancer support the diagnosis, estimation of prognosis, prediction, and monitoring of therapy response in lung cancer patients. The clinical utility of serum tumor markers has considerably increased due to developments in serum protein tumor markers analytics and clinical biomarker studies, the exploration of preanalytical and influencing conditions, the interpretation of biomarker combinations and individual biomarker kinetics, as well as the implementation of biostatistical models. In addition, circulating tumor DNA (ctDNA) and other liquid biopsy markers are playing an increasingly prominent role in the molecular tumor characterization and the monitoring of tumor evolution over time. Thus, modern lung cancer biomarkers may considerably contribute to an individualized companion diagnostics and provide a sensitive guidance for patients throughout the course of their disease. In this special edition on Tumor Markers in Lung Cancer, experts summarize recent developments in clinical laboratory diagnostics of lung cancer and give an outlook on future challenges and opportunities.

查看原文本刊更多论文

肺癌生物标志物：提高传统和新型生物标志物的临床价值。

肺癌的血液诊断有助于肺癌患者的诊断、预后评估、预测和治疗反应监测。由于血清蛋白肿瘤标志物分析和临床生物标志物研究的发展、分析前和影响条件的探索、生物标志物组合和单个生物标志物动力学的解释以及生物统计模型的实施，血清肿瘤标志物的临床实用性大大提高。此外，循环肿瘤 DNA（ctDNA）和其他液体活检标志物在肿瘤分子特征描述和监测肿瘤随时间演变方面的作用日益突出。因此，现代肺癌生物标记物可极大地促进个体化辅助诊断，并在整个疾病过程中为患者提供敏感的指导。在本期肺癌肿瘤标志物特刊中，专家们总结了肺癌临床实验室诊断的最新进展，并对未来的挑战和机遇进行了展望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tumor Biology 医学-肿瘤学

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Tumor Biology is a peer reviewed, international journal providing an open access forum for experimental and clinical cancer research. Tumor Biology covers all aspects of tumor markers, molecular biomarkers, tumor targeting, and mechanisms of tumor development and progression. Specific topics of interest include, but are not limited to: Pathway analyses, Non-coding RNAs, Circulating tumor cells, Liquid biopsies, Exosomes, Epigenetics, Cancer stem cells, Tumor immunology and immunotherapy, Tumor microenvironment, Targeted therapies, Therapy resistance Cancer genetics, Cancer risk screening. Studies in other areas of basic, clinical and translational cancer research are also considered in order to promote connections and discoveries across different disciplines. The journal publishes original articles, reviews, commentaries and guidelines on tumor marker use. All submissions are subject to rigorous peer review and are selected on the basis of whether the research is sound and deserves publication. Tumor Biology is the Official Journal of the International Society of Oncology and BioMarkers (ISOBM).